



NeuraFlex

A FlexiTab™ proprietary extended-release breakable formulation of Pregabalin

The company:

Altus is focused on developing and commercializing value-added medicines for central nervous systems.

The molecule:

Pregabalin (Lyrica®) was launched in 2004, with a CR version approved in 2017, and is a top treatment selected by physicians for the treatment of neuropathic pain.

The product:

NeuraFlex™, a value-added pregabalin in a once-daily breakable tablet format to enable flexible titration for improved patient outcomes.

The unmet patient need:

While many patients benefit from treatment with pregabalin, they are often treated with suboptimal doses, due to unfamiliarity around prescribing the drug and/or side effects that can occur with up-titration. This can lead to discontinuation and breakthrough symptoms.

The Challenge

Deliver all the clinically important benefits of pregabalin in a convenient once-a-day format with more dosing options, enabling the “low and slow” titration approach to better manage symptoms vs side-effects and **keep patients adherent to treatment.**

The Solution

NeuraFlex™ – A once-a-day breakable pregabalin XR tablet offering a greater number of dosage strengths than currently available on the market – **from a minimum number of tablets** – for simple and cost-effective titration

Experts agree that a “low and slow” approach to titration in managing neuropathic pain is key to managing side effects

Recommendations are to start pregabalin at a low dose, even as low as 25 mg/day (for older adults or frail patients) or 50 mg/day in the evening, followed by slow titration to a therapeutic dose.

NeuraFlex is **breakable**, providing more dosing options from fewer tablets, which helps patients stay on the dose that is right for them.

NeuraFlex may also benefit patients with generalized anxiety disorder, social anxiety disorder, bipolar disorder, insomnia, and Restless Leg Syndrome.

THE OPPORTUNITY

The market:

The neuropathic pain market is worth over \$8B and is expected to grow by 6% annually.

Seeking:

Partners with a focus on CNS/Pain space and/or reformulations programs interested in co-developing a new treatment to complement existing portfolios


FlexiTab™ Technology: Enabling Breakable XR Tablets

Proprietary Technology with IP granted to 2038 in the US and EU

- AmyloFlex is Altus' release modifying complex starch excipient used in all FlexiTab™ tablets
- Enables XR tablets to be broken safely to generate multiple dosages with no loss of performance
- Complies with USP, EP and JP
- Used in tablets on sale around the globe



- Drug levels from conventional XR tablets remain in the therapeutic window only when the tablets are intact
- FlexiTab™ tablets keep drug levels in the therapeutic window even when broken – with no dose dumping
- Breaking provides multiple strength tablets for flexible and precise dose titration according to specific patient needs.



Breakable XR tablets enable prescribers to titrate doses unique to each patient's needs – **without the risk of dose dumping**

PREFERRED DEAL STRUCTURE

- Upfront payment
- Licensee to assume all commercial responsibilities for the territory/territories
- Milestone payments tied to commercial achievements
- Royalties on net product sales
- Open to discussing tech transfer model to local partner site

Contact info:

busdev@altusformulation.com